In September 2021 Nikkiso Medical has graciously provided MediSieve with their PureADJUST hemoperfusion pump as part of an ongoing collaboration.
Nikkiso is one of the world's leading manufacturers of dialysis machines with a mission to keep improving the user-friendliness, safety and efficiency of the complex technology. The main focus of the company is patient safety and responsibility towards their customers. Nikkiso's products and technologies have enabled the creation of entirely new markets in Japan and throughout the world by taking on difficulties that others have deemed unachievable.
PureADJUST is a smart and compact apheresis system. The device offers clear and easy to understand display, and is versatile and easy to use. This enables MediSieve to run experiments in a simplistic and comprehensive manner. MediSieve's CEO George Frodsham has said:
"We are delighted to be working with Nikkiso to ensure that the products we are developing are compatible with their extracorporeal systems. Partnering with companies like Nikkiso is at the centre of our strategy to make sure that we successfully deliver products that are both safe and effective, providing value to patients, doctors and the wider industry."
MediSieve is grateful for this ongoing support and thanks the Nikkiso team!
More about the device:
https://www.nikkiso-europe.eu/en/products/apheresis-equipment/pureadjust-apheresemonitor
About MediSieve
MediSieve is a biotech company, developing “Magnetic Blood Filtration”, a combination of a device and a therapeutic platform of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From sepsis to malaria to leukaemia and viral infections, such as COVID-19, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.
MEDIA CONTACT:
Alina Kagermazova
alina@medisieve.co.uk
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
george@medisieve.co.uk
MediSieve Announces First Volunteer Successfully Enrolled in Phase 1 Clinical Study July 08, 2022
MediSieve at Industry Events In June 2022 June 29, 2022